Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of symptoms of depression, anxiety, burnout and post-traumatic stress among doctors, nurses and healthcare professionals on the frontlines of COVID-19. EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches aimed at promoting supportive healing with psychedelic medicine. Cybin is collaborating with a University of Washington team, led by Dr. Anthony Back, in sponsoring the trial. In the announcement, the company noted that the nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest COVID-19 patients and, as a result, have been experiencing high levels of anxiety, depression and burnout. “For more than a year now, frontline clinicians and healthcare professionals have made immeasurable sacrifices to protect public health in their communities,” said Cybin CEO Doug Drysdale in the press release. “We consider it an honor and our duty to now help support their own healing processes, post-COVID-19. We are also delighted and proud to launch EMBARK, a groundbreaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics. We look forward to working with and supporting Dr. Anthony Back on this important program.”
To view the full press release, visit https://ibn.fm/JRGBM
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics for mental illness and addiction by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment